Japan-based GHIT Fund Progress Hailed But Much To Do
This article was originally published in The Pink Sheet Daily
The GHIT Fund was set up just over two years ago to accelerate the development of drugs, vaccines and diagnostics for malaria, tuberculosis and other neglected infectious diseases affecting developing countries by building on Japan's science and research capabilities. While good progress has been made, political support and a sense of urgency are required to ensure continued impact.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context